Brief: Genprex Announces Safety Review Committee Approves Dose Escalation In Acclaim-1 Phase 1/2 Trial Of Reqorsa In Combination With Tagrisso In Non-Small Cell Lung Cancer
15/08/2022 12:30
Aug 15 (Reuters) - Genprex Inc GNPX.O :
* GENPREX ANNOUNCES SAFETY REVIEW COMMITTEE APPROVES DOSE
ESCALATION IN ACCLAIM-1 PHASE 1/2 TRIAL OF REQORSA™ IN
COMBINATION WITH TAGRISSO® IN NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nPn8cBx04a
Further company coverage: GNPX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Genprex
See all newsBrief: Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy